We are investigating Omeros Corporation (OMER) (“Omeros” or the “Company”) for potential violations of the federal securities laws.
On November 4, 2019, Omeros issued a press release announcing the results of a prospective study of the Company’s ophthalmic drug Omidria. While the study results were positive, showing significantly less fentanyl use in cataract surgery patients receiving Omidria, the press release also advised investors that the Centers for Medicare and Medicaid Services (“CMS”) had not included Omidria in the non-opioid exclusion from packaged payment in CMS’s final rule related to its outpatient prospective payment system published on November 1, 2019. On this news, Omeros’s stock price fell sharply during intraday trading on November 4, 2019.